scholarly journals Exploiting cancer’s phenotypic guise against itself: targeting ectopically expressed peptide G-protein coupled receptors for lung cancer therapy

Oncotarget ◽  
2017 ◽  
Vol 8 (61) ◽  
pp. 104615-104637 ◽  
Author(s):  
Mahjabin Khan ◽  
Tao Huang ◽  
Cheng-Yuan Lin ◽  
Jiang Wu ◽  
Bao-Min Fan ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Therapy ◽  
G Protein ◽  
G Protein Coupled Receptors ◽  
Lung Cancer Therapy ◽  
G Protein Coupled ◽  
Peptide G

G Protein-coupled Receptors in Cancer Stem Cells

2020 ◽  
Vol 26 (17) ◽  
pp. 1952-1963 ◽  
Author(s):  
Yuhong Jiang ◽  
Xin Zhuo ◽  
Canquan Mao
Keyword(s):  
Stem Cells ◽  
Cancer Therapy ◽  
Cancer Stem Cells ◽  
G Protein ◽  
Drug Targets ◽  
Underlying Mechanism ◽  
G Protein Coupled Receptors ◽  
Cell Functions ◽  
Exogenous Ligands ◽  
G Protein Coupled

G protein-coupled receptors (GPCRs) are highly expressed on a variety of tumour tissues while several GPCR exogenous ligands become marketed pharmaceuticals. In recent decades, cancer stem cells (CSCs) become widely investigated drug targets for cancer therapy but the underlying mechanism is still not fully elucidated. There are vigorous participations of GPCRs in CSCs-related signalling and functions, such as biomarkers for CSCs, activation of Wnt, Hedgehog (HH) and other signalling to facilitate CSCs progressions. This relationship can not only uncover a novel molecular mechanism for GPCR-mediated cancer cell functions but also assist our understanding of maintaining and modulating CSCs. Moreover, GPCR antagonists and monoclonal antibodies could be applied to impair CSCs functions and consequently attenuate tumour growth, some of which have been undergoing clinical studies and are anticipated to turn into marketed anticancer drugs. Therefore, this review summarizes and provides sufficient evidences on the regulation of GPCR signalling in the maintenance, differentiation and pluripotency of CSCs, suggesting that targeting GPCRs on the surface of CSCs could be potential therapeutic strategies for cancer therapy.

Peptide and non-peptide G-protein coupled receptors (GPCRs) in skeletal muscle

Peptides ◽  
2005 ◽  
Vol 26 (8) ◽  
pp. 1528-1536 ◽  
Author(s):  
Gaël Jean-Baptiste ◽  
Zhao Yang ◽  
Chamel Khoury ◽  
Sabrina Gaudio ◽  
Michael T. Greenwood
Keyword(s):  
Skeletal Muscle ◽  
G Protein ◽  
G Protein Coupled Receptors ◽  
G Protein Coupled ◽  
Peptide G

Peptide G protein-coupled receptors meet at Erice

1998 ◽  
Vol 19 (9) ◽  
pp. 343-346 ◽  
Author(s):  
Nigel W. Bunnett ◽  
Michel Bouvier ◽  
Antonio De Blasi
Keyword(s):  
G Protein ◽  
G Protein Coupled Receptors ◽  
G Protein Coupled ◽  
Peptide G

scholarly journals Bombesin Receptor Family Activation and CNS/Neural Tumors: Review of Evidence Supporting Possible Role for Novel Targeted Therapy

2021 ◽  
Vol 12 ◽  
Author(s):  
Terry W. Moody ◽  
Lingaku Lee ◽  
Irene Ramos-Alvarez ◽  
Tatiana Iordanskaia ◽  
Samuel A. Mantey ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Targeted Therapy ◽  
G Protein ◽  
Solid Tumor ◽  
G Protein Coupled Receptors ◽  
Term Survival ◽  
Bombesin Receptor ◽  
G Protein Coupled ◽  
Receptor Family

G-protein-coupled receptors (GPCRs) are increasingly being considered as possible therapeutic targets in cancers. Activation of GPCR on tumors can have prominent growth effects, and GPCRs are frequently over-/ectopically expressed on tumors and thus can be used for targeted therapy. CNS/neural tumors are receiving increasing attention using this approach. Gliomas are the most frequent primary malignant brain/CNS tumor with glioblastoma having a 10-year survival <1%; neuroblastomas are the most common extracranial solid tumor in children with long-term survival<40%, and medulloblastomas are less common, but one subgroup has a 5-year survival <60%. Thus, there is an increased need for more effective treatments of these tumors. The Bombesin-receptor family (BnRs) is one of the GPCRs that are most frequently over/ectopically expressed by common tumors and is receiving particular attention as a possible therapeutic target in several tumors, particularly in prostate, breast, and lung cancer. We review in this paper evidence suggesting why a similar approach in some CNS/neural tumors (gliomas, neuroblastomas, medulloblastomas) should also be considered.

EGFR Transactivation by Peptide G Protein-Coupled Receptors in Cancer

2016 ◽  
Vol 17 (5) ◽  
pp. 520-528 ◽  
Author(s):  
Terry W. Moody ◽  
Bernardo Nuche-Berenguer ◽  
Taichi Nakamura ◽  
Robert T. Jensen
Keyword(s):  
G Protein ◽  
G Protein Coupled Receptors ◽  
Egfr Transactivation ◽  
G Protein Coupled ◽  
Peptide G
Sign in / Sign up

Export Citation Format

Share Document